Kamal Moulana
Pulmonary Disease · Elizabethtown, KYNPI 1083626642
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $685 and has fallen 85.2% since, to $101 in 2023. That places this record below the midpoint for pulmonary disease clinicians in KY, where the typical reported total is $4,124.
Across 129 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$294
- Johnson & Johnson$215
- Novartis$208
- Seagen Inc.$168
- Merck$163
- Daiichi Sankyo Inc.$142
- plus $976 from 26 others
What the payments were for
- Food & beverage$2,10897%
- Education$593%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 17 | $294 |
| Johnson & Johnson(2 entities) | 14 | $215 |
| Novartis | 13 | $208 |
| Seagen Inc. | 10 | $168 |
| Merck | 10 | $163 |
| Daiichi Sankyo Inc. | 8 | $142 |
| AstraZeneca(2 entities) | 6 | $105 |
| Coherus Oncology, Inc. | 5 | $95 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $77 |
| Lilly USA, LLC | 5 | $73 |
| Incyte Corporation | 4 | $69 |
| Boehringer Ingelheim | 3 | $59 |
| Global Blood Therapeutics, Inc. | 3 | $48 |
| Rigel Pharmaceuticals, Inc. | 3 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Genentech USA, Inc. | 1 | $38 |
| Novo Nordisk | 2 | $37 |
| GSK | 1 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Mylan Institutional Inc. | 2 | $32 |
| Array Biopharma Inc | 2 | $30 |
| United Therapeutics Corporation | 1 | $21 |
| Partner Therapeutics, Inc. | 1 | $16 |
| Tersera Therapeutics LLC | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $15 |
| AbbVie | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Clovis Oncology, Inc. | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
| Organon | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$2,167 in reported general payments places this provider in the 35th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Elizabethtown
- Aaron MulhallElizabethtown$14K
- William CundiffElizabethtown$11K
- Navin KainiElizabethtown$11K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.